Advanced search
Publication Cover
Cancer Management and Research Volume 13, 2021 - Issue
Submit an article Journal homepage
92
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Circular RNA CircEPB41L2 Functions as Tumor Suppressor in Hepatocellular Carcinoma Through Sponging miR-590-5p

Feng Chen1 College of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, People’s Republic of China;2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China
,
Lei He2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Liman Qiu2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Yang Zhou2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Zhenli Li2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3682-164X
ORCID Icon,
Geng Chen2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Fuli Xin2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-1140-9357
ORCID Icon,
Xiuqing Dong2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Haipo Xu2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of China
,
Gaoxiong Wang4 Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362001, People’s Republic of ChinaCorrespondence[email protected]
,
Jingfeng Liu2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3499-5678
ORCID Icon &
Zhixiong Cai2 The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People’s Republic of China;3 Mengchao Med-X Center, Fuzhou University, Fuzhou, 350025, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 2969-2981 | Published online: 01 Apr 2021

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386. doi:10.1002/ijc.2921025220842
  • Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis. 2020;24:611–621. doi:10.1016/j.cld.2020.07.01333012448
  • Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.2991329624699
  • Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016;143(11):1838–1847. doi:10.1242/dev.12807427246710
  • Shang Q, Yang Z, Jia R, et al. The novel roles of circRNAs in human cancer. Mol Cancer. 2019;18(1):6. doi:10.1186/s12943-018-0934-630626395
  • Lasda E, Parker R. Circular RNAs: diversity of form and function. RNA. 2014;20(12):1829–1842. doi:10.1261/rna.047126.11425404635
  • Qu S, Yang X, Li X, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365:141–148. doi:10.1016/j.canlet.2015.06.00326052092
  • Jakobi T, Dieterich C. Computational approaches for circular RNA analysis. Wiley Interdiscip Rev RNA. 2019;10(3):e1528. doi:10.1002/wrna.152830788906
  • Bach DH, Lee SK, Sood AK. Circular RNAs in Cancer. Mol Ther Nucleic Acids. 2019;16:118–129. doi:10.1016/j.omtn.2019.02.00530861414
  • Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338. doi:10.1038/nature1192823446348
  • Guo JU, Agarwal V, Guo H, et al. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 2014;15(7):409. doi:10.1186/s13059-014-0409-z25070500
  • Fu X, Zhang J, He X, et al. Circular RNA MAN2B2 promotes cell proliferation of hepatocellular carcinoma cells via the miRNA-217/MAPK1 axis. J Cancer. 2020;11(11):3318–3326. doi:10.7150/jca.3650032231737
  • Zhang S, Liu Y, Liu Z, et al. CircRNA_0000502 promotes hepatocellular carcinoma metastasis and inhibits apoptosis through targeting microRNA-124. J BUON. 2019;24:2402–2410.31983112
  • Liu Z, Yu Y, Huang Z, et al. CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression. Cell Death Dis. 2019;10(12):900. doi:10.1038/s41419-019-2089-931776329
  • Yang X, Yu D, Ren Y, et al. Integrative functional genomics implicates EPB41 dysregulation in hepatocellular carcinoma risk. Am J Hum Genet. 2016;99(2):275–286. doi:10.1016/j.ajhg.2016.05.02927453575
  • Liu H, Liu Y, Bian Z, et al. Circular RNA YAP1 inhibits the proliferation and invasion of gastric cancer cells by regulating the miR-367-5p/p27 (Kip1) axis. Mol Cancer. 2018;17:151. doi:10.1186/s12943-018-0902-130336780
  • Wang M, Yu F, Li P. Circular RNAs: characteristics, function and clinical significance in hepatocellular carcinoma. Cancers. 2018;10(8):258. doi:10.3390/cancers10080258
  • Yao R, Zou H, Liao W. Prospect of circular RNA in hepatocellular carcinoma: a novel potential biomarker and therapeutic target. Front Oncol. 2018;8:332. doi:10.3389/fonc.2018.0033230191143
  • Xu L, Feng X, Hao X, et al. CircSETD3 (Hsa_circ_0000567) acts as a sponge for microRNA-421 inhibiting hepatocellular carcinoma growth. J Exp Clin Cancer Res. 2019;38(1):98. doi:10.1186/s13046-019-1041-230795787
  • Qiu L, Huang Y, Li Z, et al. Circular RNA profiling identifies circADAMTS13 as a miR-484 sponge which suppresses cell proliferation in hepatocellular carcinoma. Mol Oncol. 2019;13:441–455. doi:10.1002/1878-0261.1242430537115
  • Liu B, Yang G, Wang X, et al. CircBACH1 (hsa_circ_0061395) promotes hepatocellular carcinoma growth by regulating p27 repression via HuR. J Cell Physiol. 2020;235(10):6929–6941. doi:10.1002/jcp.2958932003018
  • Huang XY, Zhang PF, Wei CY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020;19:92. doi:10.1186/s12943-020-01213-632430013
  • Shen C, Wu Z, Wang Y, et al. Downregulated hsa_circ_0077837 and hsa_circ_0004826, facilitate bladder cancer progression and predict poor prognosis for bladder cancer patients. Cancer Med. 2020;9(11):3885–3903. doi:10.1002/cam4.300632250047
  • Zhang SJ, Ma J, Wu JC, et al. CircRNA EPB41L2 inhibits tumorigenicity of lung adenocarcinoma through regulating CDH4 by miR-211-5p. Eur Rev Med Pharmacol Sci. 2020;24(7):3749–3760. doi:10.26355/eurrev_202004_2083932329852
  • Jiang X, Xiang G, Wang Y, et al. MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-beta RII. Mol Cells. 2012;33:545–551. doi:10.1007/s10059-012-2267-422684895
  • Chen M, Wu L, Tu J, et al. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine. 2018;35:142–154. doi:10.1016/j.ebiom.2018.08.01030111512

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.